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A report on the Keystone Symposium ‘Biological Discovery
Using Diverse High-Throughput Data’, Steamboat Springs,
USA, 30 March-4 April 2004.
The 2004 Keystone Symposium meeting ‘Biological Discovery
Using Diverse High-Throughput Data’ was organized by
David Gifford, Edward Rubin and Richard Young. As the
title suggests, the talks at this meeting spanned a wide range
of research efforts, many of which combined various types of
computational and/or experimental data sources and
approaches. It was an outstanding meeting, with many pre-
sentations describing new developments and findings. Eric
Lander (Whitehead Institute and Massachusetts Institute of
Technology, Cambridge, USA) kicked off the meeting with a
keynote talk in which he outlined the “audacious goals” of
the genomics community: first, to sequence the entire
human genome (the only one of these goals that has been
achieved so far); second, to identify all the functional elements
in the human genome; third, to identify all signatures of
cellular responses; and fourth, to identify all common
human genetic variation. All the talks at the meeting presented
work aimed at achieving some aspect of these goals, either in
model organisms or in humans; the work being undertaken
ranged from technological to biological. 
Genome-sequence analysis and the control of
gene expression
Svante Pääbo (Max Planck Institute for Evolutionary
Anthropology, Leipzig, Germany) presented some interest-
ing findings on human-specific traits. By studying 50 ran-
domly picked olfactory receptor genes, his group found
evidence that humans are still losing functional genes.
Looking at transcription levels in different parts of human
and chimpanzee brains, Pääbo’s group has estimated that
around 10% of genes exhibit significant transcriptional dif-
ferences between human and chimpanzee, with greater
expression differences being observed in those genes with
greater sequence divergence.
The talk that aroused perhaps the most discussion was the
presentation by David Haussler (University of California,
Santa Cruz, USA) of the identification of 481 ultra-conserved
non-protein-coding regions, which are conserved across the
human, mouse and rat genomes at a level of 100% sequence
identity over at least 200 base-pairs (bp), with the largest
region spanning 779 bp. Haussler noted that most of these
ultra-conserved regions do not overlap protein-coding
regions, and those that do overlap do not extend signifi-
cantly into the protein-coding regions. Over half of the ultra-
conserved regions were found in gene deserts, with many
being over 100 kilobases (kb) away from a gene. Interest-
ingly, many of the genes flanking ultra-conserved regions
were enriched for annotation with the Gene Ontology (GO)
terms ‘development’ and ‘DNA binding’. Many of the genes
encoding exonic ultra-conserved regions were involved in
DNA or RNA binding, or were ribosomal genes. There were
many questions and much off-line discussion after this
session regarding what roles the noncoding ultra-conserved
regions might serve.
A large number of research groups are currently using phylo-
genetic footprinting to find non-protein-coding regions of
DNA that are most likely to correspond to cis-regulatory ele-
ments. Edward Rubin (Lawrence Berkeley National Labora-
tory, Berkeley, USA) presented intriguing results on
non-protein-coding regions that are conserved between
human and mouse. His group has deleted two large genomic
regions, totaling almost 3 million bp, from mice; they found
no observable phenotype in mice carrying these deletions and
only minor expression differences in the genes surrounding
the deleted conserved noncoding regions. It remains to be
seen whether these deleted conserved regions either exert an
effect on global gene expression or serve some other role in
tissues, various other settings or timeframes, or genetic back-
grounds that have not yet been assayed.A number of groups are now using in vivo genome-wide
location analysis to infer transcriptional regulatory net-
works; this technique is also known as ‘ChIP-chip’ and
involves chromatin immunoprecipitation (ChIP), followed
by hybridization to DNA microarrays to identify the
immunoprecipitated DNA. One limitation has been that thus
far essentially all yeast ChIP-chip experiments studying a
given transcription factor have been performed under just
one culture condition. Richard Young (Whitehead Institute
and Massachusetts Institute of Technology, Cambridge,
USA) announced that his group is currently performing
ChIP-chip experiments on 85 transcription factors in at least
one of 12 culture conditions in addition to rich medium.
These conditions have been selected to correspond to the
known roles of the 85 transcription factors in metabolism,
stress and development. Young noted that from analysis of
the binding of transcription factors to DNA in vivo, in rich
medium compared to conditions of amino-acid starvation,
the transcription factors can be classified into four categories
according to their binding properties: condition-invariant,
condition-enabled, condition-expanded and condition-
altered. Transcription factors that are condition invariant
occupy the same set of DNA binding sites independent of the
culture condition; condition-enabled transcription factors
occupy their sites only in a given culture condition, condition-
expanded bind a broader set of sites under particular
conditions and condition-altered bind different sets of sites
under different conditions. In a later session, David Gifford
(Massachusetts Institute of Technology, Cambridge, USA), a
close collaborator of Young’s, presented progress his group
has made in the development of algorithms for discovering
regulatory networks of gene modules, using both Young’s
ChIP-chip data and available gene-expression data. ChIP-chip
datasets from analyses of cells from various environmental
conditions and also of various kinds of cells in multicellular
organisms will help to understand the dynamic nature of
interactions between transcription factors and DNA. My own
talk followed Young’s and presented the in vitro protein-
binding microarray (PBM) technology that my lab has devel-
oped for the highly parallel, rapid characterization of the
binding specificities of transcription factors. Comparison of
PBM data with ChIP-chip data and analysis of the cross-
species sequence conservation of transcription-factor
binding sites derived from PBM analysis has allowed the
identification of many new putative targets for regulation by
yeast transcription factors. We hope that the PBM technology
will contribute to the identification of the regulatory targets
of transcription factors in various genomes. 
Bing Ren (Ludwig Institute for Cancer Research and University
of California, San Diego, USA), whose group is part of the
Encyclopedia of DNA Elements (ENCODE) Consortium,
presented new results of his group’s ChIP-chip analysis of
RNA polymerase II, TATA-binding protein (TBP) associated
factor II 250 (TAFII250), and various modified histones in
human tissue-cultured cells. The results indicate that the
binding of these factors is extremely well correlated with the
transcription start sites of genes. Ren’s presentation stimulated
much discussion about the measurement of transcription levels
throughout the genome using various microarray platforms.
Applications of genomics and proteomics
A number of the talks on proteomics focused on technological
developments. Ruedi Aebersold (Institute for Systems
Biology, Seattle, USA) presented the exciting progress that
his group is making towards the quantitative measurement
of proteins using mass spectrometry. To achieve this goal,
his group is producing ordered peptide arrays, which, when
combined with synthetic peptide standards, will allow the
absolute quantification of peptide levels. Stephen Burley
(Structural GenomiX Inc., San Diego, USA) talked about the
significant progress that Structural GenomiX has achieved
in high-throughput protein production, crystallization and
structure discovery, focusing on kinases as drug targets.
Burley stated that their pipeline, which combines structure
discovery with combinatorial chemistry, allows them to
generate a candidate drug for a particular target in roughly
6-8 months.
Moving to other methods of ‘functional genomics’, Thijn
Brummelkamp (Netherlands Cancer Institute, Amsterdam,
The Netherlands) discussed exciting work using short syn-
thetic small interfering RNAs (siRNAs) to perform RNA
interference (RNAi) screens on mammalian cells. His group
is treating cells with an RNAi library that has been bar-coded
with 59-mers, selecting cells that survive a particular stress,
using PCR to amplify DNA from survivors, and then
hybridizing the amplicons to DNA microarrays to identify
which siRNAs allowed survival. They are now screening for
siRNAs that are lethal in tumor cells but not in normal cells.
In work that is similarly directed at human health, Kelly
Frazer (Perlegen Sciences, Mountain View, USA) presented
work that Perlegen has done, using 223 high-density DNA
microarrays that cover the entire human genome, to identify
1.6 million single nucleotide polymorphisms (SNPs). Impor-
tantly, half of these SNPs were not found in the dbSNP data-
base at the National Center for Biotechnology Information
(NCBI [http://www.ncbi.nlm.nih.gov/SNP/]). Frazer stated
that Perlegen’s capacity is currently 30 million genotypes in
just one week, and that many SNPs fall outside of the 10 kb
upstream or downstream of known genes. She described
Perlegen’s work to identify SNPs that differ in groups of
individuals exhibiting low or high levels of high density
lipoprotein (HDL) cholesterol, and she noted that the
company is also examining metabolic syndromes. Kathleen
Giacomini (University of California, San Francisco, USA)
described exciting discoveries her group has made in the
pharmacogenetics of membrane transporters. She and her
colleagues found around 680 SNPs in 24 membrane trans-
porter genes; about half were coding SNPs and half of those
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group followed up by individually expressing the corre-
sponding synthetic variants in cells, 14 were non-functional
or had significantly decreased function. Of the 14 corre-
sponding SNPs, 11 were population-specific. Studies like
these will be important in understanding the variable clinical
responses that different populations have to various drugs.
In addition to SNP analyses, many groups are performing
gene-expression analysis in normal and affected individuals
with the aim of understanding a wide range of disease states,
including cancer and infection by various pathogens. Ron
Davis (Stanford University, Stanford, USA) presented impor-
tant findings his group has made concerning the significant
effects that the mode of blood collection from patients can
have on the outcomes of subsequent gene-expression analy-
sis. The results indicated that certain methods for blood col-
lection are much more reproducible than others, including
some that are currently considered standard methods for
blood collection. Davis noted that at times nurses can be
resistant to changes in the typical procedures they follow in
blood collection, but that with proper training and further
technological developments currently underway, more sensi-
tive, reproducible results could be attained.
It was apparent from this meeting that the many high-
throughput genomic and proteomic approaches that are now
available are generating complementary datasets that are
frequently being integrated into analyses aimed at under-
standing the functions of various portions of the genome and
of genomic and proteomic networks. Appropriately, towards
the end of the final presentation of the meeting, Leroy Hood
(Institute for Systems Biology, Seattle, USA) noted that
“data space is infinite”, and that “hypothesis-driven pertur-
bations must illuminate those dimensions of data space that
are biologically relevant”. Altogether, the work presented in
this meeting will help to attain the “audacious goals” that
















































































http://genomebiology.com/2004/5/7/331                                                              Genome Biology 2004, Volume 5, Issue 7, Article 331 Bulyk  331.3
Genome Biology 2004, 5:331